e-ISSN: 2617-7668     print ISSN: 2522-9176
The use of the drug prothrombin complex Octaplex for various bleeding in patients with deficiency of factor X
##common.pageHeaderLogo.altText## EURASIAN JOURNAL OF CLINICAL SCIENCES

Abstract

The relevance of adequate treatment of various bleeding in patients with coagulopathy is due to the wide spread of this condition with deficiencies of various blood clotting factors.
Purpose. The purpose of the study was to study the results of using the Octaplex prothrombin complex in patients with deficiency of the X factor and in patients with the acquired form of hemophilia.
Materials and methods of the study. Under our supervision there were 27 patients with deficiency of factor X. All patients with various forms of bleeding were undergoing hospital treatment and follow-up at the Republican Center for Hemophilia Mountains. Baku of the Azerbaijan Republic. The study had a retrospective character. To assess hemostasis, the following laboratory parameters were used: activity of blood factors VIII, VII, Xi et al, APTT, PI, PV, INR, bleeding time by Li Uayt, fibrinogen.

References

Зубаиров Д.М. Молекулярные основы свертывания крови и тромбообразования. Казань, 2000, 364 с.

Н.Н. Мамаева, С.И.Рябов, Гематология ,2008, 543 с.

Мамот А.П. Патология гемостаза принципы и алгоритмы клинико-лабораторной диагностики.СПБ. формат Т. 2006, 208 с.

Мамаев А.Н. Коагулопатии: руководство, Москва, 2012, 264 с.

Руководство по гематологии в 3 I. под.ред. А.И. Воробьева. Москва, 2005.

Рукавицын О.А. Гематология Москва,2015, 770 с.

Ellis Neufeld Current risks limitations of living with severe haemophiliaA.Symposium 10 th Annual Congress of EAHAD, 2017.

Giralami A, Scarparo R, Allemand E. Congenitae factorX deficiencies with a defect only or predominantly in the axtrinsic or in the intrinsic system: a critical evaluation. Am Y Haemotol.2008, 83:668-71.

Textbook of Hemophilia Christine Lee, Erik Berntop, Keith Hoots, 464 p.

Tai S, Herzog RW, Margaritis P. et.al. Aviable mouse model of factor X deficiency provides evidence for maternal transfer of factor X. J ThrombHaemost 2008, 6:339-45

Todd T, Perry D, Hayman E, Lawrence K, Gattens M, Baglin T. Severe factor X deficiency due to a homozygous mutation (Cys 364 Arg) that discrupts a disulphide bond in the catalytic domain. Haemophilia 2006, 12:621-4.

PDF (Русский)
PDF (Русский)

Keywords

treatment
Octaplex
factor X лечения
Октаплекс
фактор Х müalicə
Oktapleks
faktor X